PGE2 levels and heart duct closure in preterm babies
Treatments studied
Part of Genetic & congenital, Heart & circulation, Women’s health & pregnancy clinical trials.
This trial measures a substance called prostaglandin E2 (PGE2) in preterm babies to see if it can predict whether a heart blood vessel (ductus arteriosus) will close on its own or need treatment. This could help doctors decide when to use medication to close the vessel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Born at 32 weeks or earlier
- Diagnosed with patent ductus arteriosus (PDA) by heart ultrasound on day 3 of life
- No major chromosome or birth defects
- No serious bleeding in the brain that is getting worse
- No other heart defects besides PDA or a small hole (PFO)
- No lung blood pressure that causes blood to flow backward
- No conditions that prevent using ibuprofen (including low urine output, high creatinine, low platelets, abnormal bleeding tests, or severe gut infection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain signs seen on ultrasound can help doctors manage a common heart condition in premature babies called patent ductus arteriosus (PDA). Your baby's heart ultrasound will be checked for these signs, which may guide treatment decisions.
This study tests a personalized approach to treating a common heart condition in very early preterm babies, where a blood vessel (the ductus arteriosus) stays open. It aims to find the best time and way to close this vessel using medication, based on the baby's specific biomarkers.
This Phase 2 study tests whether giving ibuprofen together with acetaminophen improves outcomes for an important heart connection (PDA) in extremely premature infants. It compares how this medicine approach affects the baby’s heart-related measurements and short-term progress.
This study tests a personalized way to give ibuprofen to very premature babies with a heart condition called PDA. It aims to see if adjusting the dose can help close the heart opening more safely.
This trial compares an early procedure to close a heart vessel called the ductus arteriosus versus careful observation alone in very low-birth-weight preterm infants. It aims to see whether closing the vessel early can improve outcomes and be done safely.
This trial creates a registry to gather information on premature babies who have a PDA (an open blood vessel in the heart) and are getting it closed with a catheter-based device. It helps doctors learn more about how safe and effective this treatment is for these tiny babies.
Hear when a new Neonatal Prematurity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.